Invention Grant
- Patent Title: Composition for treating mental illness
-
Application No.: US17071236Application Date: 2020-10-15
-
Publication No.: US11241425B2Publication Date: 2022-02-08
- Inventor: Daniel R. Deaver , Mark Todtenkopf
- Applicant: Alkermes Pharma Ireland Limited
- Applicant Address: IE Dublin
- Assignee: Alkermes Pharma Ireland Limited
- Current Assignee: Alkermes Pharma Ireland Limited
- Current Assignee Address: IE Dublin
- Agency: Goodwin Procter LLP
- Main IPC: A61K31/485
- IPC: A61K31/485 ; C07D221/28 ; A61K9/20 ; A61K31/439 ; A61K31/496 ; A61K31/5513 ; A61K31/551 ; A61K31/554 ; C07D405/06 ; A61K31/519
Abstract:
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Public/Granted literature
- US20210046065A1 Methods for Treating Antipsychotic-Induced Weight Gain Public/Granted day:2021-02-18
Information query
IPC分类:
